Cabotegravir

CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically…

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: APRETUDE is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition.
Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP.
Do not take if: with unknown or positive HIV-1 status.
with previous hypersensitivity reaction to cabotegravir.
receiving the following coadministered drugs for which significant decreases in cabotegravir plasma concentrations may occur due to uridine diphosphate glucuronosyltransferase (UGT)1A1 enzyme induction, which may result in reduced effectiveness:
o Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin

What it is used for

APRETUDE is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP.

Side effects, and when to stop

The following adverse reactions are described below and in other sections of the labeling:

Hypersensitivity reactions
Hepatotoxicity
Depressive disorders

Who should not take it

APRETUDE is contraindicated in individuals:

with unknown or positive HIV-1 status.
with previous hypersensitivity reaction to cabotegravir.
receiving the following coadministered drugs for which significant decreases in cabotegravir plasma concentrations may occur due to uridine diphosphate glucuronosyltransferase (UGT)1A1 enzyme induction, which may result in reduced effectiveness:
- o Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin
- o Antimycobacterials: Rifampin, rifapentine

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Cabotegravir; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/cabotegravir
APA 7th: sofidex. (2026, August 2). Cabotegravir. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/cabotegravir
AMA 11th: Cabotegravir. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/cabotegravir

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.